TEMPE, Ariz., Oct. 13, 2009 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) today announced the presentation of pre-clinical data at the American College of Surgeons 95th Annual Clinical Conference in Chicago, IL, demonstrating significant benefit of Chrysalin(R) (rusalatide acetate or TP508) in a model of acute heart disease and elevated cholesterol. The data, as previously announced and as originally published in April 2009, demonstrate that Chrysalin, administered following the onset of ischemia, showed a statistically significant cardioprotective benefit in an elevated-cholesterol porcine model of acute myocardial infarction (AMI or heart attack).
